Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
Haliton Alves de Oliveira JúniorTiago Pereira da VeigaFrancisco de Assis AcurcioAlessandra Maciel AlmeidaJéssica Barreto Ribeiro Dos SantosMichael Ruberson Ribeiro da SilvaAdriana Maria KakehasiMariângela Leal CherchigliaPublished in: Hospital practice (1995) (2020)
Patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis displayed significantly better QoL levels following treatment with DMARDs.